Aesthetic industry veteran Todd Zavodnick has been appointed chief executive officer (CEO) of Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences. Zavodnick has more than 20 years of leadership experience in the biopharmaceutical industry. He joins Dermavant from Revance, a biotechnology company where he served as chief commercial officer and president of aesthetics and therapeutics. Prior to Revance, he held global leadership roles at ZELTIQ Aesthetics and Galderma Laboratories where he was president and general manager of North America.
Dermavant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for inflammatory skin diseases and medical dermatologic conditions. The company's existing development pipeline consists of five product candidates targeting five different conditions with significant unmet medical needs. Dermavant's lead product candidate, tapinarof (DMVT-505), is an investigational topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) that is being developed as a potential first-line topical treatment for psoriasis and atopic dermatitis.
“It is an honor to join Dermavant at such an exciting time in the company's growth,” said Zavodnick. “Medical dermatology is a therapeutic area in need of real innovation, and that is precisely what we intend to provide at Dermavant.”
Image: Todd Zavodnick
